Post by Harvard University

A new oral medication has been shown to significantly improve overall survival and progression-free survival in patients with advanced pancreatic cancer. The findings—led by Harvard Medical School, Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, and the University of California—support the use of the drug as the new standard of care for patients whose metastatic pancreatic cancer has progressed after initial treatment.